1984:  GSK/WRAIR initiate collaboration  First clinical tests in humans begin in adults in US		Key Cone in ch		y Proof-of- ncept study children in pzambique Phase III study start			2011:  Phase III study  First results in 5- 17 month olds 12 months follow up published in NEJM		Phase III study Results over 18 months follow-up first presented at MIM PAN African Malaria Conference with publication in PLoS Medicine 2014		Phase III study Final results including 3-4 years of follow-up and 4th dose of RTS,S administered 18 months after the third dose published in The Lancet	
1987:  RTS,S first created by combining the malaria CS protein and hepatitis B	1997:  Key proof-of- concept study shows 6 out o volunteers in challenge trial ne fully protected	f 7 <b>2001:</b> I are GSK/MVI	GSK/MVI partnership		2007:  Phase II results in African children and infants published in The Lancet and NEJM		2011:  Key Phase II efficacy results in African children and infants published in the Lancet and NEJM		2012:  Phase III study  Second set of results in 6-12 week olds 12 month follow up published in the NEJM		itted :MA)	2015: EMA Positive Scientific Opinion granted

surface antigen

2015: